Sirtuins (SIRT1-7) are a highly conserved family of NAD þ -dependent enzymes that control the activity of histone and nonhistone regulatory proteins. SIRT1 is purposed to promote longevity and to suppress the initiation of some cancers. Nevertheless, SIRT1 is reported to function as a tumor suppressor as well as an oncogenic protein. Our data show that compared with normal liver or surrounding tumor tissue, SIRT1 is strongly overexpressed in human hepatocellular carcinoma (HCC). In addition, human HCC cell lines (Hep3B, HepG2, HuH7, HLE, HLF, HepKK1, skHep1) were screened for the expression of the sirtuin family members and only SIRT1 was consistently overexpressed compared with normal hepatocytes. To determine its effect on HCC growth, SIRT1 activity was inhibited either with lentiviruses expressing short hairpin RNAs or with the small molecule inhibitor, cambinol. Knockdown or inhibition of SIRT1 activity had a cytostatic effect, characterized by an altered morphology, impaired proliferation, an increased expression of differentiation markers, and cellular senescence. In an orthotopic xenograft model, knockdown of SIRT1 resulted in 50% fewer animals developing tumors and cambinol treatment resulted in an overall lower tumor burden. Taken together, our data show that inhibition of SIRT1 in HCC cells impairs their proliferation in vitro and tumor formation in vivo. These data suggest that SIRT1 expression positively influences the growth of HCC and support further studies aimed to block its activity alone or in combination as a novel treatment strategy. Mol Cancer Ther; 12(4); 499-508. Ó2013 AACR.
Introduction
Sirtuins are a highly conserved family of enzymes that are homologues to the silent information regulator (Sir) 2 gene family found in yeast. The sirtuin family consists of 7 members (SIRT1-7) that share a highly conserved catalytic core domain and rely on NAD þ for their enzymatic function. The family members differ in their N-and C-terminal extensions and in their subcellular localization, which together are responsible for their various binding partners and diverse metabolic functions (1) . (Additional information on sirtuin family members (SIRT2-7) is provided in the Supplementary Data).
SIRT1 is the best-studied family member because of its purported ability to prolong the lifespan in Caenorhabditis elegans, Drosophila melanogaster, and mammals (2) (3) (4) (5) . SIRT1 deacetylates histone proteins and other key transcriptional regulators such as p53 (6) (7) (8) , NF-kB (9), Foxo (10), Ku70 (11) , E2F1 (12) , PPARg coactivator 1a (PGC-1a; ref. 13) , and hypoxia-inducible transcription factors (HIF; [14] [15] [16] . Its broad effect on gene transcription has centralized its role in cellular events involved in aging, metabolism, inflammation, and stress responses (17) . In the past decade, a controversial view of SIRT1 has emerged about its role in tumorigenesis. SIRT1 is found to be overexpressed in many cancers such as prostate, colon, and acute myeloid leukemia (18) (19) (20) . Nevertheless, it is reported to function as a tumor promoter and as a tumor suppressor protein. The indeterminate role of SIRT1 suggests that its involvement in tumorigenesis may differ between tumor types and depend on the temporal or spatial distribution of upstream and downstream factors that regulate its function (21) .
In this study, we investigated the expression of SIRT1 in the context of hepatocellular carcinoma (HCC). HCC is the third most common cause of cancer-related deaths worldwide (22) . It is a highly aggressive cancer with a complex and multimodal pathogenesis (23) . Only early stages of HCC are curable with today's treatment protocols, therefore new therapeutic strategies are currently needed. Whole-genome sequencing of HCCs has identified recurrent mutations in chromatin regulators that can directly influence chromatin's structure and activity. (24) . Chromatin regulators exert posttranslational modifications of histone proteins by altering their methylation, ubiquitinylation, and acetylation status and have a direct influence on gene expression. Histone deacetylases (HDAC) in particular, class I and II HDACs are being targeted with compounds such as panobinostat as a novel treatment strategy for HCC (25, 26) . Sirtuins make up the class III HDACs and therefore may represent another class of chromatin regulators for potential targeting.
In this study we show that SIRT1 is frequently overexpressed in human HCC and HCC cell lines. Inhibition of SIRT1 activity results in the impairment of tumor cell growth and increased expression of differentiation markers in in vitro and in vivo models. These observations suggest that SIRT1 expression promotes the growth of HCC and new treatment strategies inhibiting its activity may be a novel means for the treatment of HCC.
Materials and Methods

Immunohistochemistry
Human liver and HCC samples were obtained from consented patients in our institution by standard surgical oncology procedures. Tissue samples from patients diagnosed with HCC were compared with samples taken from tumour-free resection margins or nontumor liver. SIRT1 was detected using a rabbit polyclonal anti-SIRT1 antibody (Santa Cruz Biotechnology). Additional details can be found in Supplementary Materials and Methods.
Cell culture and human tissue
All HCC cell lines were from human origin. Hep3B and HepG2 cells were purchased from American Type Culture Collection (LCG Promochem). HLE, HLF, HepKK1, and skHep1 cell lines were kindly provided by L. Wilkens (University of Bern, Bern, Switzerland) and HuH7 cells by J.-F. Dufour (University of Bern, Bern, Switzerland). All lines were tested for mycoplasma contamination and only lines testing negative were used in the study. The HCC cell lines were not authenticated further. Cells were cultured in Dulbecco's Modified Eagle's Medium with 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin (Life Technology) at 37 C in a humidified incubator with 5% CO 2 . For primary human hepatocytes, liver specimens were obtained from patients undergoing liver resection. Informed consent was obtained before surgery in compliance with the local ethical committee. Details of the isolation method can be found in Supplementary Materials and Methods. Hypoxic culture conditions were conducted in a microaerophilic system (Ruskinn, Biotrace International) at 1% O 2 , 5% CO 2 , and 94% N 2 .
Chemicals and reagents
Cambinol and nocodazole (Sigma-Aldrich) were solved in dimethyl sulfoxide (DMSO) as stock solutions (cambinol 100 mmol/L; nocodazole 5 mg/mL). D-luciferin (Synchem OHG) was dissolved in saline (250 mmol/L) at the time of use.
RNA extraction and reverse transcriptasequantitative PCR
RNA was isolated by TRIzol Reagent and followed the manufacturer's protocol (Life Technologies). cDNA was synthesized by using Omniscript RT Kit 200 (cat. no. 205113, Qiagen). mRNA was analyzed by reverse transcriptase-quantitative PCR (RT-qPCR; ABI 7900, SDS 2.3 software). A detailed description of probes and primers can be found in the Supplementary Materials and Methods.
Proliferation assays
Proliferation assays (alamarBlue, mitotic index, colony formation, and EdU incorporation) are described in detail in the Supplementary Materials and Methods.
Senescence-associated b-galactosidase staining
Cells fixed with 2% formaldehyde and 0.2% glutaraldehyde were incubated for 14 hours with staining solution (40 mmol/L citric acid sodium phosphate, pH 6.0,
. Photographs were taken with a Nikon camera.
Cell-cycle analysis by FACS
Cells fixed with 70% EtOH were incubated for 2 hours with RNase A (40 ug; Promega)/propidium iodide solution (50 ug; Sigma-Aldrich). Cell-cycle distribution was determined by fluorescence-activated cell sorting (FACS) using the LSR II and FACSDiva software (Becton Dickinson).
Caspase-3 assay
Caspase-3 assay was determined using fluorogenic caspase- 3 Lentivirus production, titer determination, and transduction were carried out as previously described (35) . A detailed description can be found in the Supplementary Materials and Methods.
Statistical analysis
All graphs represent mean value of triplicates AE SD. Statistics were conducted using unpaired Student t-test and graphs made using GraphPad Prism software, with definitions for P-values as follows:
ÃÃ , P ¼ 0.001-0.01 (very significant); ÃÃÃ , P < 0.0001 (extremely significant).
Results
SIRT1 is overexpressed in HCC and liver cancer cell lines
SIRT1 protein expression was examined in a panel of 20 human HCC tumors and adjacent nontumor tissue by immunohistochemistry. We observed a strong distinct staining for SIRT1 with predominant nuclear localization in tumor cells, whereas SIRT1 protein expression in normal or adjacent nonmalignant liver was minimal or absent (Fig. 1A ). Samples were scored for intensity of SIRT1 staining and average tumor score (2.00 AE 0.58, P < 0.001) and maximum tumor score (2.5 AE 0.7, P < 0.001) were both significantly higher than adjacent nonmalignant liver (1.0 AE 0.07; Fig. 1B) . Nevertheless, the levels of SIRT1 mRNA were not significantly different in 8 samples of HCC and paired nontumor liver (Fig. 1C) . We next determined if other sirtuin family members were overexpressed in HCC, by comparing mRNA expression of SIRT1-7 in 7 human liver cancer cell lines to nonmalignant primary human hepatocytes. Of the sirtuin family members, only SIRT1 mRNA was significantly increased in 6 of the 7 cell lines (Fig. 1D) . The other family members, SIRT2 (Fig. 1E ) and SIRT3-7 ( Supplementary Fig. S1 ) were expressed at equal or lower levels (exceptions: SIRT5 and SIRT7 in Hep3B and HepG2; SIRT6 in Hep3B). Similar results were obtained by analyzing the protein expression of SIRT1 and SIRT2 by Western blot analysis. SIRT1 protein was consistently expressed at higher levels in HCC cells lines, whereas, equal or lower levels were observed for SIRT2 (Fig. 1F) .
Knocking down SIRT1 has a cytostatic effect in HCC cell lines
To determine whether SIRT1 is essential for HCC cell growth, SIRT1 was knocked down with lentiviruses expressing shRNAs (shSIRT1_3206 and shSIRT1_1958) in HepG2 (Fig. 2) and Hep3B and HuH7 cell lines (Supplementary Fig. S2 ). SIRT1 knockdowns were compared with a scrambled control (shScr). SIRT1 mRNA expression was significantly reduced in shSIRT1 infected cells ( Fig. 2A and Supplementary Fig. S2A ) with a coinciding loss of protein ( Fig. 2B and Supplementary Fig. S2B ). Clone shSIRT1_1958, targeting SIRT1 on the coding DNA sequence was more efficient than clone shSIRT1_3206, which targets SIRT1 mRNA in the 3 0 -untranslated region. SIRT2 protein ( S2C ) was not decreased when SIRT1 mRNA was targeted, however, an increase of its mRNA, was observed in cells transduced with clone shSIRT1_1958.
The morphology of cells infected with shSIRT1 viruses was transformed into a larger, flattened shape compared with shScr and noninfected controls (Fig. 2C  Supplementary Fig. S2D ). Morphologic changes in HepG2 cells were associated with a decrease in proliferation, measured by colony formation (Fig. 2D ) and alamarBlue assays (Fig. 2E) . Phosphorylation of histone 3, a marker of cells exiting mitoses was lower in SIRT1 knockdown cells (Fig. 2F ) and this was associated with more cells arrested in G 1 and less in S-phase of the cell cycle (Fig. 2G ). There were no visual signs of cell death or a measurable increase in activity of the apoptotic protein caspase-3 (data not shown). A characteristic of HCC cells is the expression of poorly differentiatiated markers glypican (GPC3) and a-fetoprotein (AFP) and a loss of the epithelial marker E-cadherin (CDH1). Loss of SIRT1 led to a significant decrease in AFP and GPC3 ( Fig. 2H and Supplementary Fig. S2E ) and an increase of CDH1 mRNA expression (Fig. 2H) . Interestingly, a stable SIRT1 knockdown line was unable to be generated in Hep3B and HuH7 cells. Their complete lack of growth was accompanied with an induction of cellular senescence as shown by enlarged cell size and expression of pH-dependent b-galactosidase activity (Supplementary Fig. S2F ). Taken together, these data suggest that loss of SIRT1 has a cytostatic effect on HCC cells by arresting cells in G 1 thus leading to a lower mitotic index and impairment of cell proliferation. The change in their morphology was accompanied by changes of differentiation markers and in Hep3B and HuH7 cells an induction of cellular senescence could be observed.
Knocking down SIRT1 reduces tumor formation in an orthotopic xenograft model
We next tested the effect of SIRT1 knockdown in vivo using an orthotopic xenograft mouse model. To monitor tumor growth noninvasively, a tagged HepG2 cell line was generated with a luciferase containing lentivirus. The resulting HepG2_luc cells were further infected with shScr, shSIRT_3206, or shSIRT1_1958 shRNA and selected cells were injected subcapsularly in the liver of immune deficient mice. Tumor growth was measured by bioluminescent imaging (Fig. 3A) . Although 60% of the mice developed tumors in the control group after day 4 and 80% after day 11, the animals harboring cell lines with knocked down SIRT1 expression formed tumors in 50% of the animals for the shSIRT1_3206 and only 33% for the shSIRT1_1958 for up to 30 days (Fig. 3B) . In HepG2_luc þshSIRT1 cells, we observed either a complete lack of tumor formation or tumor growth was delayed, as they never reached an exponential growth phase compared with the shScr control group (Fig. 3C) . Histologic analysis of tumors with SIRT1 knockdown revealed a reduced number of intratumoral blood vessels (Fig. 3D ). This impairment of tumor angiogenesis is supported by our observation that hypoxia-induced VEGF expression is inhibited in SIRT1 knockdown cells (Fig. 3E) . A, RT-qPCR of SIRT1 mRNA. B, Western blot analysis for SIRT1 and SIRT2. b-Actin was used as a loading control. C, effect on cellular morphology was detected by microscopy, Â200. D, colony formation assay, stained with crystal violet. Proliferation was measured by conducting alamarBlue assay, detected as relative light units (RLU; E) and a mitotic index assay, expressed as relative phosphorylated H3 levels (F). G, cell-cycle analysis was conducted by FACS and expressed as% Watson pragmatic. H, RT-qPCR for AFP, GPC3, and CDH1 expression.
SIRT1 is a potential drug target
We next questioned whether SIRT1 could be a target for pharmacologic intervention. SIRT1 was inhibited with cambinol, a cell permeable b-naphthol pharmacophore that blocks its NAD þ -dependent deacetylase activity (Fig. 4) . Cambinol altered the morphology of 2 HCC cell lines, with a more striking change observed in HepG2 cells (Fig. 5A ) than in Hep3B cells (Supplementary Fig. S3A ). The morphologic changes were not associated with visible signs of cell death or with activity of the apoptotic protein caspase-3 (Fig. 5B) . Inhibition of SIRT1 reduced colony formation in a (Fig. 5C and Supplementary  Fig. S3B ) and fewer colonies were reflected by a significant decrease in the percentage of proliferating, EdU positive cells (Fig. 5D) . Interestingly, cambinol lead to a G 1 arrest only in p53wt-HepG2 cells, not p53del-Hep3B ( Fig. 5E and Supplementary Fig. S3C ). As we observed in SIRT1 knockdown cells, cambinol reduced the expression of poorly differentiatiated markers AFP and GPC3 ( Fig. 5F and Supplementary Fig. S3D ). And finally, cambinol impaired cell migration in a dose-dependent manner (Supplementary Fig. S3E ).
Using an orthotopic xenograft model, we next tested if cambinol could impair HCC growth in vivo. First, to determine if cambinol had a hepatotoxic effect itself, mice were treated daily with 50 and 100 mg/kg cambinol for 2 weeks. At the end of treatment, we conducted a 70% partial hepatectomy to assess liver damage as an impairment of regeneration. Serum alanine aminotransferase levels were not increased in cambinol-treated animals ( Supplementary Fig. S3F ). Moreover, cambinol did not impair the regenerative capacity of normal liver compared with vehicle only controls ( Supplementary  Fig. S3G ). Nonetheless, in animals harboring HCC xenografts, tumor growth was impaired in animals treated with cambinol starting on day 8 posttumor cell injection (Fig 5G) . Tumors in vehicle-treated animals reached an exponential growth rate starting on day 16, whereas cambinol suppressed tumor growth in 3 animals and reverted tumor growth in 1 animal after day 23. Taken together, our data show that inhibiting SIRT1 activity in HCC tumor cells leads to a decrease in cell proliferation, an increase of differentiation, and impaired tumor growth in vivo, whereas, it does not impair the proliferative potential of normal liver parenchyma.
Discussion
Current literature describes how activation of SIRT1 is able to prevent the development of age or carcinogeninduced cancers. For example, Herranz and colleagues showed that transgenic animals overexpressing SIRT1 are protected against diethylnitrosamine/high fat dietinduced liver carcinogenesis compared with nontransgenic controls (27) . The protective effect was explained, in part, by SIRT1-mediated regulation of NF-kB activity; SIRT1 overexpression reduced NF-kB-mediated inflammation and hepatic cell malignant transformation. Although SIRT1 expression is purposed to prevent HCC in this model, we observed a strong overexpression of SIRT1 in human HCC tumors and HCC cell lines. This observation confirms other studies that have documented SIRT1 overexpression in panels of human HCC samples (28) (29) (30) . In cancer research, there are more examples emerging of how malignant cells have the ability to hijack survival mechanisms used by nonmalignant cells for their own endurance (31, 32) . These observations prompted our laboratory to hypothesize that SIRT1 activity in healthy liver tissue may provide protection against malignancy, however after transformation, SIRT1 expression or its overexpression may be providing a protective or survival advantage for the tumor cells. Our data supports this by demonstrating that inhibition of SIRT1 in HCC cells by knockdown with shRNA or with the inhibitor cambinol can impair tumor cell growth in vitro and in vivo. This is the first preclinical study in HCC to show that inhibition of SIRT1 impairs tumor cell growth in animal models and that it is possible to use small molecule inhibitors to achieve an antitumor effect in vitro and in vivo and collectively suggest that SIRT1 may be a novel target for cancer therapy.
In our study, we inhibited SIRT1 with the small molecule inhibitor cambinol that previously was shown to impair the growth of Burkitt lymphoma xenografts (33) . Interestingly, cambinol did not impair a normal physiologic growth response in nonmalignant liver cells, as mice treated with cambinol displayed no signs of hepatic damage or impairment of liver cell proliferation in response to partial hepatectomy. In agreement, it was previously shown that knockdown of SIRT1 with siRNA led to growth arrest in human epithelial cancer cell lines but not primary epithelial cells (34) and that cambinol is well tolerated by mice in the absence of other noxious stimuli (33) . SIRT1 is not a specific target of cambinol, it also inhibits SIRT2 NAD-dependent deacetylase activity in vitro with IC 50 values of 56 and 59 mmol/L, respectively (33) . Although it has been previously shown that combined SIRT1 and SIRT2 inhibition induces cell death, we observed a cytostatic as opposed to a cytotoxic effect in cells treated with cambinol (35) .
SIRT1 has a direct effect on cell survival and proliferation by targeting key transcription factors such as FOXO, E2F1, and p53 (referenced in Introduction) and can promote cancer cell growth by blocking cellular senescence and differentiation (36) . Therefore, and as shown here, inhibition of SIRT1 removes this growthpromoting signal and forces cells in a nonproliferating, senescent, or more differentiated phenotype. Regardless of their p53 status, wild-type (HepG2), null (Hep3B), or mutated (HuH7), all lines overexpressed SIRT1 and all responded to SIRT1 inhibition with an inhibition of cell proliferation. Therefore, the cytostatic effect achieved was not dependent on functioning p53. As p53 activity is impaired by SIRT1 we expected a stronger effect with SIRT1 inhibition in p53wt cells. However, in the absence of other stresses or DNAdamaging agents, it was the p53-mutated and null cells that showed a profound inhibition of cell proliferation and induction of cellular senescence by SIRT1 inhibition. As we observed cellular senescence by SIRT1 inhibition this further supports a cytostatic effect, as senescence is an arrested state in which cells still remain viable. When examining the differentiation state of cells with altered SIRT1 expression or activity, we observed a loss of expression of the malignancy markers AFP and GPC3. GPC3 promotes growth of HCC cells through stimulation of the canonical Wnt signaling pathway that regulates the expression of many downstream oncogenic proteins. A recent study has shown that molecular targeting of GPC3 enhanced TGF-b2 expression and signaling, which in turn inhibited HCC cell proliferation and cell-cycle progression, and induced replicative senescence (37) . Loss of expression of AFP and GPC3 together with an increase of CDH1 suggests that cells are gaining a more differentiated phenotype. This observation might be beneficial as poorly differentiated cancer cells are more resistant to conventional chemotherapies (38) . Further studies will determine whether SIRT1 has a direct effect on AFP and GPC3 gene expression, as it has since been shown that SIRT1 localizes to the promoter element of E-cadherin to repress its expression directly (39) .
SIRT1 was strongly expressed in human samples of HCC and it appears that its overexpression is unique as the other family members displayed equal or lower protein levels. mRNA analysis of HCC cell lines suggested that SIRT1 was transcriptionally increased in liver cancer cell liens. The transcription of SIRT1 is negatively regulated by the tumor suppressor proteins p53 and HIC1, both of which are frequently mutated in cancers. Nonetheless, this observation did not correspond with our patient samples; an increase of SIRT1 protein was not associated with an increase of its mRNA, suggesting a posttranslational stabilization of its protein. It is still unclear at which point and by which mechanism HCC cells gain and become reliant on SIRT1 expression. It has been suggested that SIRT1 is critical in all stages of tumor formation (reviewed in ref. 40 ). However, it still needs to be determined if SIRT1 overexpression is indeed an initiating event, as no tumors were reported to be induced in SIRT1 overexpressing transgenic mice, in fact, these mice had fewer spontaneous carcinomas and sarcomas (27, 41) . Further investigations may reveal that as important as SIRT1 overexpression is, perhaps equally important is loss of expression of other family members, for example SIRT3 and SIRT6 in promoting tumor growth in HCC.
Our study supports SIRT1 as a novel therapeutic target for the treatment of HCC. Although our results suggest that targeting SIRT1 may be effective as a single modality, the cytostatic rather than cytotoxic effect of SIRT1 inhibition suggests that targeting SIRT1 in combination with other cancer therapies to enhance sensitivity and to impair tumor cell escape mechanisms may be a future approach. 
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